Middle East and Africa Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)

Code: TIPRE00028620 | Pages: 152 | Industry: Pharmaceuticals | Date: Apr 2022 | Type: Regional

The Middle East & Africa monoclonal antibodies market is expected to reach US$ 5,741.1 million by 2028 from US$ 3,198.9 million in 2021. The market is estimated to grow at a CAGR of 8.7% from 2021–2028.

The high focus of pharmaceutical giants on developing novel monoclonal antibodies resulted in significant research collaborations that can pave the way to key market share in the coming years. New manufacturers seek strategic collaborations to increase uptake of such novel techniques, as they intend to enter a highly competitive market to sustain their position. For records, in October 2017, Incyte and MacroGenics, Inc. announced a partnership and license agreement for "MGA012", an investigational monoclonal antibody of MacroGenics, Inc. Such factors are projected to support the Middle East & Africa market growth in the coming years. Furthermore, strategic research collaborations also play a vital role in detecting pharmacological actions of mABs soon after the diagnosis.

 

The demand for monoclonal antibody-based products in Saudi Arabia have a high success rate in clinical development and is reported that the probability of FDA approvals for mABs in Phase 1 of development in ~14.1% that is almost twice the approval rate of small molecule drugs (~7.6%). On the other hand, the IAVI report states that with the onset of pandemic worldwide many biopharmaceutical companies sell mABs based products at affordable prices. For example, in South Africa, Roche sells its breast cancer mAB "trastuzumab" as both Herceptin the original brand as a second brand called "Hercelon". Apart from that, as availability of these mABs is limited, various pharmaceutical companies are conducting clinical trials in middle-income counties. For example, Merck is conducting clinical trials in several middle-income countries such as South Africa, Colombia, and Malaysia. Such aforementioned factors have positive influence in the regional market thereby witnessing high adoption of monoclonal antibody in Middle East and Africa region amid COVID-19 pandemic.

 

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the monoclonal antibodies market. The Middle East & Africa monoclonal antibodies market is expected to grow at a good CAGR during the forecast period.

 

Middle East & Africa Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Monoclonal Antibodies Market Revenue and Forecast to 2028 (US$ Million)

Get more information on this report :


Middle East & Africa Monoclonal Antibodies Market Segmentation        

By Source

  • Human
  • Humanized
  • Chimeric
  • Murine 

By Production Method

  • In-Vitro
  • In-Vivo

By Indication

  • Cancer
  • Autoimmune Diseases
  • Infectious Diseases
  • Inflammatory Diseases
  • Microbial Diseases
  • Others

By Application

  • Therapeutic Applications
  • Diagnostic Applications
  • Research Applications

By End-User

  • Hospitals
  • Research Institutes
  • Others

By Country

  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Companies Mentioned

  • Novartis AG
  • Pfizer Inc.
  • GlaxoSmithKline plc.
  • Amgen Inc
  • DAIICHI SANKYO COMPANY, LIMITED
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Source

1.3.2        Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Production Method

1.3.3        Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Indication

1.3.4        Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Application

1.3.5        Middle East & Africa Monoclonal Antibodies (mAbs) Market – By End-User

1.3.6        Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Geography

2.           Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Monoclonal Antibodies (mAbs) Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        Middle East & Africa PEST Analysis

4.3         Experts Opinion

5.           Monoclonal Antibodies (mAbs) Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Rising Prevalence of Cancer and Other Chronic Diseases

5.1.2        mABs Uptake Proves to be Effective During Pandemic Outbreak

5.2         Market Restraints

5.2.1        Low Awareness, Accessibility, and High Cost

5.3         Market Opportunities

5.3.1        Cost-effective Advanced Technology for Developing mABs Presents Billion-Dollar Opportunity

5.4         Future Trends

5.4.1        Strategic Research Collaborations

5.5         Impact Analysis

6.           Monoclonal Antibodies (mAbs) Market– Middle East & Africa Analysis

6.1         Middle East & Africa Monoclonal Antibodies (mAbs) Market, By Geography - Forecast and Analysis

7.           Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028– by Source

7.1         Overview

7.2         Middle East & Africa Monoclonal Antibodies (mAbs) Market, By Source, 2020 & 2028 (%)

7.3         Murine

7.3.1        Overview

7.3.2        Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.4         Chimeric

7.4.1        Overview

7.4.2        Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.5         Humanized

7.5.1        Overview

7.5.2        Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

7.6         Human

7.6.1        Overview

7.6.2        Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

8.           Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Production Method

8.1         Overview

8.2         Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)

8.3         In-Vivo

8.3.1        Overview

8.3.2        In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

8.4         In-Vitro

8.4.1        Overview

8.4.2        In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.           Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Indication

9.1         Overview

9.2         Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)

9.3         Cancer

9.3.1        Overview

9.3.2        Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.4         Autoimmune Diseases

9.4.1        Overview

9.4.2        Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.5         Inflammatory Diseases

9.5.1        Overview

9.5.2        Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.6         Infectious Diseases

9.6.1        Overview

9.6.2        Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.7         Microbial Diseases

9.7.1        Overview

9.7.2        Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

9.8         Others

9.8.1        Overview

9.8.2        Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10.        Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – Application

10.1      Overview

10.2      Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)

10.3      Diagnostic Applications

10.3.1     Overview

10.3.2     Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10.4      Therapeutic Applications

10.4.1     Overview

10.4.2     Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

10.5      Research Applications

10.5.1     Overview

10.5.2     Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11.        Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 – End-User

11.1      Overview

11.2      Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)

11.3      Hospitals

11.3.1     Overview

11.3.2     Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11.4      Research Institutes

11.4.1     Overview

11.4.2     Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

11.5      Others

11.5.1     Overview

11.5.2     Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecast to 2028 (US$ Million)

12.        Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 – Geographical Analysis

12.1      Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028

12.1.1     Overview

12.1.2     Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.1.3     Middle East & Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.1.4     Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)

12.1.5     Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.1.6     Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.7     Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

12.1.8     Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)

12.1.8.1       UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.1.8.1.1       Overview

12.1.8.1.2       UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.1.8.1.3       UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.1.8.1.4       UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)

12.1.8.1.5       UAE: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.1.8.1.6       UAE: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.8.1.7       UAE: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

12.1.8.2       Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.1.8.2.1       Overview

12.1.8.2.2       Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.1.8.2.3       Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.1.8.2.4       Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028, By Production (US$ Million)

12.1.8.2.5       Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.1.8.2.6       Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.8.2.7       Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

12.1.8.3       South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.1.8.3.1       Overview

12.1.8.3.2       South Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

12.1.8.3.3       South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

12.1.8.3.4       South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Production (US$ Million)

12.1.8.3.5       South Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

12.1.8.3.6       South Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.8.3.7       South Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

13.        Impact Of COVID-19 Pandemic on Monoclonal Antibodies (mAbs) Market

13.1      Middle East & Africa: Impact Assessment of COVID-19 Pandemic

14.        Monoclonal Antibodies (mAbs) Market–Industry Landscape

14.1      Overview

14.2      Growth Strategies Done by the Companies in the Market, (%)

14.3      Organic Developments

14.3.1     Overview

14.4      Inorganic Developments

14.4.1     Overview

15.        Company Profiles

15.1      Novartis AG

15.1.1     Key Facts

15.1.2     Business Description

15.1.3     Products and Services

15.1.4     Financial Overview

15.1.5     SWOT Analysis

15.1.6     Key Developments

15.2      Pfizer Inc.

15.2.1     Key Facts

15.2.2     Business Description

15.2.3     Products and Services

15.2.4     Financial Overview

15.2.5     SWOT Analysis

15.2.6     Key Developments

15.3      GlaxoSmithKline plc.

15.3.1     Key Facts

15.3.2     Business Description

15.3.3     Products and Services

15.3.4     Financial Overview

15.3.5     SWOT Analysis

15.3.6     Key Developments

15.4      Amgen Inc.

15.4.1     Key Facts

15.4.2     Business Description

15.4.3     Products and Services

15.4.4     Financial Overview

15.4.5     SWOT Analysis

15.4.6     Key Developments

15.5      DAIICHI SANKYO COMPANY LIMITED

15.5.1     Key Facts

15.5.2     Business Description

15.5.3     Products and Services

15.5.4     Financial Overview

15.5.5     SWOT Analysis

15.5.6     Key Developments

15.6      F. HOFFMANN-LA ROCHE LTD.

15.6.1     Key Facts

15.6.2     Business Description

15.6.3     Products and Services

15.6.4     Financial Overview

15.6.5     SWOT Analysis

15.6.6     Key Developments

15.7      AstraZeneca

15.7.1     Key Facts

15.7.2     Business Description

15.7.3     Products and Services

15.7.4     Financial Overview

15.7.5     SWOT Analysis

15.7.6     Key Developments

15.8      Bayer AG

15.8.1     Key Facts

15.8.2     Business Description

15.8.3     Products and Services

15.8.4     Financial Overview

15.8.5     SWOT Analysis

15.8.6     Key Developments

15.9      Bristol-Myers Squibb Company

15.9.1     Key Facts

15.9.2     Business Description

15.9.3     Products and Services

15.9.4     Financial Overview

15.9.5     SWOT Analysis

15.9.6     Key Developments

16.        Appendix

16.1      About The Insight Partners

16.2      Glossary of Terms

 


LIST OF TABLES

Table 1.             Middle East & Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 2.             Middle East & Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 3.             Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 4.             Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 5.             Middle East & Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 6.             UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 7.             UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 8.             UAE: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 9.             UAE: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 10.          UAE: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 11.          Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 12.          Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 13.          Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 15.          Saudi Arabia: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 16.          South Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Source (US$ Million)

Table 17.          South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Production (US$ Million)

Table 18.          South Africa: Monoclonal Antibodies (mAbs) Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 19.          South Africa: Monoclonal Antibodies (mAbs) Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 20.          South Africa: Monoclonal Antibodies (mAbs) Market, by End-User – Revenue and Forecast to 2028 (US$ Million)

Table 21.          Organic Developments Done by Companies

Table 22.          Inorganic Developments Done by Companies

Table 23.          Glossary of Terms

 


LIST OF FIGURES

Figure 1.           Monoclonal Antibodies (mAbs) Market Segmentation

Figure 2.           Middle East & Africa Monoclonal Antibodies (mAbs) Market Overview

Figure 3.           Human Segment Held Largest Share of Source Segment in Monoclonal Antibodies (mAbs) Market

Figure 4.           South Africa is Expected to Show Remarkable Growth During the Forecast Period

Figure 5.           Middle East & Africa Monoclonal Antibodies (mAbs) Market, Industry Landscape

Figure 6.           Middle East & Africa: PEST Analysis

Figure 7.           Experts Opinion

Figure 8.           Impact Analysis of Drivers and Restraints Pertaining to Monoclonal Antibodies (mAbs) Market

Figure 9.           Middle East & Africa Monoclonal Antibodies (mAbs) Market – By Geography Forecast and Analysis – 2021 - 2028

Figure 10.        Middle East & Africa Monoclonal Antibodies (mAbs) Market, by Source, 2020 & 2028 (%)

Figure 11.        Murine: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 12.        Chimeric: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 13.        Humanized: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 14.        Human: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 15.        Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Production Method Segment - 2020 & 2028 (%)

Figure 16.        In-Vivo: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 17.        In-Vitro: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 18.        Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Indication Segment - 2020 & 2028 (%)

Figure 19.        Cancer: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 20.        Autoimmune Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 21.        Inflammatory Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 22.        Infectious Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 23.        Microbial Diseases: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 24.        Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 25.        Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by Application Segment - 2020 & 2028 (%)

Figure 26.        Diagnostic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 27.        Therapeutic Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 28.        Research Applications: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 29.        Middle East & Africa Monoclonal Antibodies (mAbs) Market Share by End-User Segment - 2020 & 2028 (%)

Figure 30.        Hospitals: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 31.        Research Institutes: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 32.        Others: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts To 2028 (US$ Million)

Figure 33.        Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue Overview, by Country, 2021 (US$ Million)

Figure 34.        Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 35.        Middle East & Africa Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028, By Country (%)

Figure 36.        UAE: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 37.        Saudi Arabia: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 38.        South Africa: Monoclonal Antibodies (mAbs) Market Revenue and Forecasts to 2028 (US$ Million)

Figure 39.        Impact of COVID-19 Pandemic in Middle East & Africa Country Markets

Figure 40.        Growth Strategies Done by the Companies in the Market, (%)

  1. Novartis AG
  2. Pfizer Inc.
  3. GlaxoSmithKline plc.
  4. Amgen Inc
  5. DAIICHI SANKYO COMPANY, LIMITED
  6. F. Hoffmann-La Roche Ltd.
  7. AstraZeneca
  8. Bayer AG
  9. Bristol-Myers Squibb Company
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3000
Site License
$4000
Enterprise License
$5000